Results 91 to 100 of about 2,207,775 (300)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study

Breast Cancer Research
Background Chidamide is an oral subtype-selective histone deacetylase inhibitor that has been used as an anti-cancer agent. This study evaluated the efficacy and safety of chidamide plus fulvestrant in the treatment of HR-positive and HER2-negative ...
La Zou, Xianjun Tang, Pan Deng, Yijing Liu, Ti Yang, Xin Tan, Lu Yang, Wei Li, Xiaohua Zeng   +8 more
doaj   +1 more source

Outcomes and risk of subsequent breast events in breast‐conserving surgery patients with BRCA1 and BRCA2 mutation

Cancer Medicine, 2020
Purpose Previous studies provide inconsistent interpretations of the effect of inherited genetic factors on the survival and prognosis of patients with breast cancer. The aim of this study was to examine the effect of germline BRCA1 and BRCA2 mutation on
Fugui Ye, Liang Huang, Guantian Lang, Xin Hu, Genhong Di, Zhimin Shao, Ayong Cao   +6 more
doaj   +1 more source

Hereditary Breast Cancer [PDF]

Acta Oncologica, 1999
Information on genetics is in process of exponential growth, with a corresponding recognition that most medical information, screening and diagnostic tests, and disease processes have a genetic component. Hereditary breast cancer is a good example, showing the complexity of cancer genetics in a clinical context.
openaire   +3 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons

Journal of Cancer Research and Clinical Oncology
Purpose This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression.
Hui-Ai Zeng, Hui-Min Lv, Meng-Wei Zhang, Li-Min Niu, Jing Wang, Hui-Hui Sun, Zhen-Zhen Liu, Min Yan   +7 more
doaj   +1 more source

CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism. [PDF]

, 2018
CD44 is a single-pass cell surface glycoprotein that is distinguished as the first molecule used to identify cancer stem cells in solid tumors based on its expression.
Gao, Ruifang, Li, Dan, Li, Jun, Li, Xiru, Liu, Chen, Luo, Na, Qiao, Huan, Shen, Wenzhi, Stupack, Dwayne G, Wang, Juan, Xun, Jing, Zhou, Wei   +11 more
core  

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Breast cancer

Morecambe Bay Medical Journal, 1960
     
openaire   +2 more sources

Breast cancer

Journal of the Royal College of Physicians of Edinburgh, 2010
Breast cancer is now the most common cancer of women in the UK and incidence is increasing. Because of major treatment advances and earlier diagnosis over the past 40 years, survival rates have been improving gradually and women diagnosed with breast cancer today are almost twice as likely to survive for 10 years or longer as women 40 years ago ...
openaire   +2 more sources